Glutamate receptor ionotropic NMDA type subunit 1 (GluN1 (also known as NR1))

Glutamate receptor ionotropic NMDA type subunit 1—commonly referred to as GluN1 or NR1—is an essential component of the N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptors. The protein is encoded by the GRIN1 gene. It forms part of a heterotetrameric complex that constitutes functional NMDA receptors together with other subunits such as GluN2A-D and sometimes GluN3A-B. The GluN1 subunit is obligatory for all functional NMDA receptors; it binds glycine or D-serine as a coagonist alongside glutamate. NMDA receptors are ligand-gated cation channels highly permeable to calcium ions (Ca2+), sodium (Na+), and potassium (K+). They play a critical role in excitatory neurotransmission, synaptic plasticity—including mechanisms underlying learning and memory—and various forms of neural development. Activation requires both ligand binding and membrane depolarization to relieve magnesium block within the pore. Dysfunction or dysregulation involving this subunit has been implicated in numerous CNS diseases including neurodegenerative disorders, psychiatric illnesses such as schizophrenia and bipolar disorder, epilepsy, chronic pain syndromes, among others. Several drugs target this site either directly by blocking its activity noncompetitively within the channel pore (memantine, ketamine), competitively at agonist/coagonist sites, or allosterically through modulators like zinc. Therapeutic targeting must balance efficacy against risks such as excitotoxicity from overactivation—which can lead to neuronal injury—or cognitive/psychotomimetic side effects from excessive inhibition.[1][2][3][4]

Other names

NMDAR1NR1GRIN1 (gene name)GluN1 subunit

Noncompetitive antagonism at the NMDA receptor channel pore (e.g., memantine, ketamine block the open channel) Competitive antagonism at glutamate or glycine binding sites Allosteric modulation via zinc or polyamines binding to regulatory sites on the receptor complex